According to media reports on April 23rd, synthetic biology company Biocreatech (Shenzhen) Biotechnology Co., Ltd. (referred to as ” Biocreatech “) announced the completion of tens of millions of yuan in Series A financing. This financing round was led by Triwise Capital, with Guangdong Technology Financial Group participating, and WinX Capital as the exclusive financial advisor.
As per official introductions, Biocreatech was established in 2019 and is headquartered in Shenzhen. The company has established research and development and pilot production bases covering an area of 3,000 square meters in Shenzhen and Tianjin and is actively constructing a green biofactory. The company is dedicated to continuous innovation, industrialization, and commercialization of synthetic biology pipelines in fields such as personal care, pet healthcare, and biopesticides. It has also collaborated with leading global beauty and chemical companies.
The report pointed out that the proceeds from this financing round will be used to accelerate the industrialization and commercialization of leading targeted fungicidal proteins, anti-aging peptides, collagen proteins, and bio-based surfactant pipelines, focusing on skin health and green beauty. Additionally, existing technologies will be iteratively upgraded to meet market demand, and more competitive synthetic biology products will be developed based on market needs.
Biocreatech Biotechnology’s founder, Zhang Jiaquan, publicly expressed gratitude to the investors in this round of funding, stating, “We appreciate the support from this round of investors for Biocreatech. Based on a deep understanding of the future trends in synthetic biology, we believe that the company can use the most innovative technologies to address the current development challenges in traditional industries, achieve high-quality applications of green production methods, and contribute to China’s advancement in the bio-manufacturing strategy.”
Dr. Leng Xiaoyao from Triwise Capital also commented, “Driven by policies related to the bio-economy and the development of low-carbon economies, the synthetic biology industry has ushered in historic development opportunities. Biocreatech has established a full-chain synthetic biology platform around precise protein design and protein molecular machine technology. With a focus on commercialization, the company conducts reverse selection, focusing on efficient biosynthesis in areas such as skin health and daily care. We believe that Biocreatech can quickly grow into a benchmark enterprise in the field of synthetic biology.”
According to reports, the company was also crowned the champion in the “Foresee New Product Research” track of the 2021 L’Oréal BIG BANG Global Beauty Tech Competition. It has established long-term strategic partnerships with multinational enterprises such as L’Oréal, Evonik, BASF, and Syngenta.
